BEGIN:VCALENDAR PRODID:-//Microsoft Corporation//Outlook 16.0 MIMEDIR//EN VERSION:2.0 METHOD:PUBLISH X-MS-OLK-FORCEINSPECTOROPEN:TRUE BEGIN:VTIMEZONE TZID:Romance Standard Time BEGIN:STANDARD DTSTART:16011028T030000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 END:STANDARD BEGIN:DAYLIGHT DTSTART:16010325T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT CATEGORIES:Grøn kategori CLASS:PUBLIC CREATED:20190906T111956Z DESCRIPTION:\nDEBAT\n\n\nHVORDAN SIKRER VI DANMARK SOM LIFE SCIENCE-NATION? \n\n\n \n\n\n \n\n\nBIOTECH - FROM RESEARCH TO PRODUCTS. HOW CAN WE BUIL D A LIFE SCIENCE POWERHOUSE IN DENMARK?\n\n\nDr. Hans Schambye\, CEO\, Gal ecto Biotech\n\nThe Danish Life Science industry is a remarkable strong po int for Denmark. The Danish life science export has increased from about 4 % of the total export in the nineties to more than 16% today.\nThe sector provides solutions to patients all over the World. More than 50% of the gl obal market for hearing aids are manufactured by Danish companies\, while Denmark is the site of production for about half of all insulin sold in th e world. Furthermore\, the sector contributes DKK 21 billion annually in c orporate and personal taxes\, hence plays a key role for the Danish welfar e state.\nIt is crucial that more life science startups are created and bu ilt in Denmark in order to continue this impressive trajectory. The Danish universities generate top class science\, but way too little of this rese arch is transformed into new companies. Further\, promising companies are typically sold to foreign acquirers rather than developed into strong and independent export successes. This is to a large extent caused by poorer b asic conditions for life science startups in Denmark compared to the surro unding countries. For instance\, tax deductions for R&D expenses should be improved to make it attractive to invest in research in Denmark. Further\ , it is hard to attract risk capital because our capital gains tax is the second highest among the OECD countries. Improving the conditions for life science companies is a very good investment – it generates novel treatm ents and solutions that help people around the World and leads to strong r eturns through more well paid jobs\, tax revenues and increased export.\n \n\n \n \n DTEND;TZID="Romance Standard Time":20190924T152000 DTSTAMP:20190906T111956Z DTSTART;TZID="Romance Standard Time":20190924T150000 LAST-MODIFIED:20190906T111956Z PRIORITY:5 SEQUENCE:0 SUMMARY;LANGUAGE=da:DiaLabXpo: Tuesday 24. september\, Dr. Hans Schambye: B ioTech - From research to products. How can we build a life science powerh ouse in Denmark TRANSP:OPAQUE UID:040000008200E00074C5B7101A82E0080000000080388747B564D501000000000000000 010000000CBB50AFD7499CE4497DF3E1AF2311B83 X-ALT-DESC;FMTTYPE=text/html:

DEBAT

HVORDAN SIKRER VI DANMA RK SOM LIFE SCIENCE-NATION? \; \;

 \;

 \ ;

BIOTECH - FROM RESEARCH TO PRODUCTS. HOW CAN WE BUILD A LIFE SCIENCE POWE RHOUSE IN DENMARK?


Dr. Hans Schambye \, CEO\, \;Galecto Biotech

The Danish Life Science industry is a remarkab le strong point for Denmark. The Danish life science export has increased from about 4% of the total export in the nineties to more than 16% today.< /span>

The sector provides soluti ons to patients all over the World. More than 50% of the global market for hearing aids are manufactured by Danish companies\, while Denmark is the site of production for about half of all insulin sold in the world. Furthe rmore\, the sector contributes DKK 21 billion annually in corporate and pe rsonal taxes\, hence plays a key role for the Danish welfare state.

It is crucial that more life science startups are created and built in Denmark in order to continue this impressive trajectory. The Danish univer sities generate top class science\, but way too little of this research is transformed into new companies. Further\, promising companies are typical ly sold to foreign acquirers rather than developed into strong and indepen dent export successes. This is to a large extent caused by poorer basic co nditions for life science startups in Denmark compared to the surrounding countries. For instance\, tax deductions for R&\;D expenses should be i mproved to make it attractive to invest in research in Denmark. Further\, it is hard to attract risk capital because our capital gains tax is the se cond highest among the OECD countries. Improving the conditions for life s cience companies is a very good investment –\; it generates novel tre atments and solutions that help people around the World and leads to stron g returns through more well paid jobs\, tax revenues and increased export.

 \;

 \;

 \;

X-MICROSOFT-CDO-BUSYSTATUS:BUSY X-MICROSOFT-CDO-IMPORTANCE:1 X-MICROSOFT-DISALLOW-COUNTER:FALSE X-MS-OLK-CONFTYPE:0 BEGIN:VALARM TRIGGER:-PT15M ACTION:DISPLAY DESCRIPTION:Reminder END:VALARM END:VEVENT END:VCALENDAR